News

In these new findings, investigators highlight phase 1 research into ritlecitinib for patients aged 6 to 12 years with alopecia areata.

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.

A study found 1 in 7 children with anaphylaxis experience biphasic reactions after epinephrine, with no recurrences after 4 hours, highlighting corticosteroid impact.

GLP-1 RA use was associated with a lower risk of major cardiovascular events, clinically significant portal hypertension, and all-cause mortality in MASLD.

Avapritinib 25mg daily significantly improved quality of life (QoL), disease control, and basal serum tryptase (BST) levels.

Iron administration was linked to a decrease in platelet counts, even in the absence of preexisting thrombocytosis.

These data point to inaccessibility, distance from providers, and insurance-related barriers as obstacles to mental health improvement among children with atopic dermatitis.

A pooled analysis of LIBERTY-CSU CUPID Study A and Study C showed dupilumab reduces itch in patients with chronic spontaneous urticaria by week 24.

The analysis of 2004-2024 Google Trends data revealed varying levels of public interest in IgAN, MD, FSGS, LN, and DN.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

Children with urticaria or angioedema face greater risks of adverse events after COVID-19 vaccination, but most tolerate subsequent doses with proper management.

An approval for sparsentan in focal segmental glomerulosclerosis would mark the second rare kidney disease approval for the agent.

Exposure to aspirin and NSAIDs was linked to a reduced risk of cancer incidence and overall mortality in patients with chronic liver diseases.

Data from the CAFETERIA trial provide insight into exposure vs avoidance strategies for high-threshold peanut allergy.

Cardiovascular hospitalization rates were higher in the US than in Denmark, driven by a significant increase in heart failure and myocardial infarction hospitalizations.

An analysis found anaphylaxis following non-COVID vaccines is rare, with greater rates for yellow fever and influenza vaccines.

Test your knowledge of the 2023 Anaphylaxis Update from the Joint Task Force on Practice Parameters, focusing on diagnoses and biomarkers!

Barnes explains the significance of having mirikizumab as a treatment option for Crohn’s disease and reviews new VIVID-2 open-label extension data.

The drug given this designation, known as rezpegaldesleukin, is indicated for adult and pediatric patients aged 12 years and older with atopic dermatitis.

Boehringer plans to soon submit a new drug application for nerandomilast for treating PPF to the FDA.

Announced by LIB Therapeutics Inc., the agency has set a PDUFA target action date of December 12, 2025.

This announcement by INmune Bio, Inc., follows positive findings in the MissionEB clinical trial evaluating CORDStrom for treatment of recessive dystrophic epidermolysis bullosa.

In this study, investigators highlighted factors associated with active hidradenitis suppurativa over the age of 50 such as smoking, male gender, and later onset of disease.

The Fast Track Designation was granted to Biodexa Pharmaceuticals’ eRapa based on phase 2 data showing its safety and tolerability in adults with FAP.

A study found a strong link between headache disorders and suicide risk, including tension-type headaches.

Use of medications for secondary CVD prevention is low globally, and in most country income-level groups, with no indication of improvement.

Our top 5 headlines include a trial of gene-edited pig kidneys, a first-of-its-kind antibiotic approval, and new guidelines for migraine.

In this analysis, investigators conclude that health-related quality of life and clinical burdens are greater among patients with hidradenitis suppurativa and draining tunnels.